ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Several groups showed that CML-iPSCs do not respond to treatment with imatinib at the pluripotent undifferentiated state, despite BCR-ABL expression, indicating that they are not dependent on BCR-ABL at this cellular state.